Dosing & Uses
Acute Myeloid Leukemia
Pending FDA approval for relapsed or resistant acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) (r/r FLT3-ITD AML)
Next:
Pharmacology
Mechanism of Action
Inhibits FMS-like tyrosine kinase 3 (FLT3), and thereby, inhibits FLT3 receptor signally and proliferation in cells exogenously expressing FLT3
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
